子痫前期14,15-EET、15-HETE表达及妊娠结局分析  

Levels of 14,15-EET and 15-HETE in preeclampsia and analysis of pregnancy outcomes

作　　者：杨佳琪 曹雪燕 薛云薇 施建[2] 黄华[3] 苏敏[1] YANG Jiaqi;CAO Xueyan;XUE Yunwei;SHI Jian;HUANG Hua;SU Min(Department of Obstetrics and Gynecology,Affiliated Hospital of Nantong University,Jiangsu 226001;Enzymology Laboratory,Affiliated Hospital of Nantong University,Jiangsu 226001;Department of Pathology,Affiliated Hospital of Nantong University,Jiangsu 226001)

机构地区：[1]南通大学附属医院妇产科,江苏226001 [2]南通大学附属医院酶学实验室,江苏226001 [3]南通大学附属医院病理科,江苏226001

出　　处：《交通医学》2023年第5期441-444,共4页Medical Journal of Communications

基　　金：江苏省妇幼保健科研项目(F201905);南通市科技计划项目(JC2021045)。

摘　　要：目的:研究妊娠期高血压疾病(hypertensive disorder of pregnancy,HDP)孕妇及正常孕妇孕晚期血清花生四烯酸代谢产物14,15-环氧二十碳烯酸(14,15-epoxyeicosatrienoic acid,14,15-EET)和15-羟二十烷四烯酸(15-hydroxyeicosateraenoic acid,15-HETE)的表达差异及其与妊娠结局的关系。方法:选取子痫前期及正常分娩各6例胎盘组织,采用液相色谱联合质谱分析胎盘组织中花生四烯酸19种代谢产物含量。选取妊娠期高血压疾病患者149例(其中妊娠期高血压53例,子痫前期51例,重度子痫前期45例)作为观察组,正常健康孕妇50例为对照组。采用酶联免疫吸附实验检测血清14,15-EET及15-HETE水平。将重度子痫前期分为不良妊娠结局组20例和正常妊娠结局组25例,比较两组血清14,15-EET及15-HETE水平。结果:子痫前期患者胎盘中14,15-EET、15-HETE及9-羟基十八碳二烯酸(9-hydroxy octadecadienoic acid,9-HODE)含量较对照组增多,差异均有统计学意义(P<0.05)。血清14,15-EET及15-HETE水平重度子痫前期组高于子痫前期组、妊娠期高血压组和对照组,子痫前期组高于妊娠期高血压组和对照组,妊娠期高血压组高于对照组,差异均有统计学意义(P<0.05)。重度子痫前期妊娠不良结局组血清14,15-EET及15-HETE水平高于妊娠正常结局组,差异均有统计学意义(P<0.01)。结论:14,15-EET和15-HETE可能参与妊娠期高血压疾病的病理生理过程,重度子痫前期孕妇血清14,15-EET及15-HETE水平增高与妊娠不良结局有关。[Abstract] Objective: To investigate the level difference of arachidonic acid metabolites 14,15-epoxyeicosatrienoic acid (14,15-EET) and 15-hydroxyeicosateraenoic acid (15-HETE) in the serum of pregnant women with hypertensive disorder of pregnancy (HDP) and normal pregnant women at third trimester and their relationship with pregnancy outcomes. Methods: Placental tissues of 6 cases of preeclampsia and 6 cases of normal delivery were selected, and the contents of 19 metabolites of arachidonic acid in placental tissues were analyzed by liquid chromatography combined with mass spectrometry. 149 cases of pregnant women with HDP (including 53 cases of gestational hypertension, 51 cases of preeclampsia and 45 cases of severe preeclampsia) were selected as the observation group and 50 normal pregnant women as the control group. The serum levels of 14,15-EET and 15-HETE were detected by enzyme-linked immunosorbent assay. Severe preeclampsia was divided into two groups: 20 cases with the bad pregnancy outcome and 25 cases with the normal pregnancy outcome. The serum levels of 14,15-EET and 15-HETE were compared between the two groups. Results: The contents of 14,15-EET, 15-HETE and 9-hydroxy octadecadienoic acid(9-HODE) in placenta of preeclampsia patients were higher than those in the control group, with statistical difference (P<0.05). The serum levels of 14,15-EET and 15-HETE in the severe preeclampsia group were higher than those in the preeclampsia group, gestational hypertension group and control group, with statistically significant difference (P<0.05). The serum levels of 14,15-EET and 15-HETE in the group with bad pregnancy outcome of severe preeclampsia were higher than those in the group with normal pregnancy outcome, with statistical difference (P<0.01). Conclusion: 14,15-EET and 15-HETE may be involved in the pathophysiology of HDP and the increase of serum 14,15-EET and 15-HETE levels in pregnant women with severe preeclampsia were associated with the adverse pregnancy outcomes.

关 键 词：14 15-环氧二十碳烯酸 15-羟二十烷四烯酸 花生四烯酸代谢产物 妊娠期高血压疾病 子痫前期 

分 类 号：R714.246[医药卫生—妇产科学]